- The FDA advisory panel's recent decision significantly impacts GSK's stock performance.
- Analysts provide mixed projections, highlighting both potential upside and caution.
- GuruFocus metrics suggest a promising outlook for long-term investors.
Advisors to the U.S. FDA have advised against approving GSK's (GSK, Financial) drug Blenrep when used in combination with other medications for certain cancer treatments. This recommendation, citing a less favorable benefit-risk ratio, has resulted in a notable 5% decline in GSK's stock value. Investors are now eagerly awaiting the FDA's final decision, expected by July 23, to see how it will impact GSK's market standing.
Wall Street Analysts Forecast
According to price targets from 7 analysts over the next year, GSK PLC (GSK, Financial) holds an average target price of $39.23. Forecasts range from a high of $45.00 to a low of $34.10, suggesting an average potential upside of 8.01% from the current stock price of $36.32. Investors looking for more comprehensive estimate data should visit the GSK PLC (GSK) Forecast page.
The average brokerage recommendation for GSK PLC, based on input from 9 firms, stands at 2.9, classifying it as a "Hold." This rating operates on a scale from 1 to 5, where 1 is a Strong Buy and 5 is a Sell.
From the perspective of GuruFocus estimates, the projected GF Value for GSK PLC (GSK, Financial) in the upcoming year is $46.52. This indicates a possible upside of 28.09% from its current price of $36.3179. The GF Value reflects an estimate of the stock's fair trading value, calculated based on historical trading multiples, as well as past and projected business performance. For additional data, visit the GSK PLC (GSK) Summary page.
